Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
Ryan A. Wilcox, Andrew L. Feldman, David A. Wada, et al.
Blood (2009) Vol. 114, Iss. 10, pp. 2149-2158
Open Access | Times Cited: 209

Showing 1-25 of 209 citing articles:

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, et al.
New England Journal of Medicine (2014) Vol. 372, Iss. 4, pp. 311-319
Open Access | Times Cited: 3359
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 23, pp. 2698-2704
Open Access | Times Cited: 937
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen, Bjoern Chapuy, Jing Ouyang, et al.
Clinical Cancer Research (2013) Vol. 19, Iss. 13, pp. 3462-3473
Open Access | Times Cited: 800
Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen, Bryan Irving, F. Stephen Hodi
Clinical Cancer Research (2012) Vol. 18, Iss. 24, pp. 6580-6587
Closed Access | Times Cited: 605
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Aaron M. Goodman, Sandip Pravin Patel, Razelle Kurzrock
Nature Reviews Clinical Oncology (2016) Vol. 14, Iss. 4, pp. 203-220
Closed Access | Times Cited: 416
Regulatory T Cells in Cancer
Dimitrios Mougiakakos, Aniruddha Choudhury, Álvaro Lladser, et al.
Advances in cancer research (2010), pp. 57-117
Closed Access | Times Cited: 383
Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
Xavier Frigola, Brant A. Inman, Christine M. Lohse, et al.
Clinical Cancer Research (2011) Vol. 17, Iss. 7, pp. 1915-1923
Open Access | Times Cited: 336
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
Elizabeth R. Plimack, Joaquim Bellmunt, Shilpa Gupta, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 2, pp. 212-220
Closed Access | Times Cited: 323
Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
David Andorsky, Reiko Yamada, Jonathan W. Said, et al.
Clinical Cancer Research (2011) Vol. 17, Iss. 13, pp. 4232-4244
Open Access | Times Cited: 314
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
Blanca Homet Moreno, Antoni Ribas
British Journal of Cancer (2015) Vol. 112, Iss. 9, pp. 1421-1427
Open Access | Times Cited: 233
PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
Bradley M. Haverkos, Diana Abbott, Mehdi Hamadani, et al.
Blood (2017) Vol. 130, Iss. 2, pp. 221-228
Open Access | Times Cited: 227
Immune checkpoints in the tumor microenvironment
Salman M. Toor, Varun Sasidharan Nair, Julie Decock, et al.
Seminars in Cancer Biology (2019) Vol. 65, pp. 1-12
Closed Access | Times Cited: 196
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study
Michael S. Khodadoust, Alain H. Rook, Pierluigi Porcu, et al.
Journal of Clinical Oncology (2019) Vol. 38, Iss. 1, pp. 20-28
Open Access | Times Cited: 191
Immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma
Yi Lin, Michael P. Gustafson, Peggy A. Bulur, et al.
Blood (2010) Vol. 117, Iss. 3, pp. 872-881
Open Access | Times Cited: 231
Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
Jennifer M. Boland, Eugene D. Kwon, Susan M. Harrington, et al.
Clinical Lung Cancer (2012) Vol. 14, Iss. 2, pp. 157-163
Closed Access | Times Cited: 180
The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma
Ryan A. Wilcox, Kay M. Ristow, Thomas M. Habermann, et al.
Leukemia (2011) Vol. 25, Iss. 9, pp. 1502-1509
Closed Access | Times Cited: 180
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia
Fabienne McClanahan, Bola S. Hanna, Shaun Miller, et al.
Blood (2015) Vol. 126, Iss. 2, pp. 203-211
Open Access | Times Cited: 176
Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing
Ti‐Hsuan Ku, Tiantian Zhang, Hua Luo, et al.
Sensors (2015) Vol. 15, Iss. 7, pp. 16281-16313
Open Access | Times Cited: 170
GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features
Tianjiao Wang, Andrew L. Feldman, David A. Wada, et al.
Blood (2014) Vol. 123, Iss. 19, pp. 3007-3015
Open Access | Times Cited: 169
T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells
Imane Azzaoui, Fabrice Uhel, Delphine Rossille, et al.
Blood (2016) Vol. 128, Iss. 8, pp. 1081-1092
Open Access | Times Cited: 151
Expression and function of PD‐1 in human γδ T cells that recognize phosphoantigens
Masashi Iwasaki, Yoshimasa Tanaka, Hirohito Kobayashi, et al.
European Journal of Immunology (2010) Vol. 41, Iss. 2, pp. 345-355
Open Access | Times Cited: 148
Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas
Dohee Kwon, Sehui Kim, Pil‐Jong Kim, et al.
Histopathology (2015) Vol. 68, Iss. 7, pp. 1079-1089
Closed Access | Times Cited: 144
Cutaneous T‐cell lymphoma: 2017 update on diagnosis, risk‐stratification, and management
Ryan A. Wilcox
American Journal of Hematology (2017) Vol. 92, Iss. 10, pp. 1085-1102
Open Access | Times Cited: 141
Cutaneous T‐cell lymphoma: 2016 update on diagnosis, risk‐stratification, and management
Ryan A. Wilcox
American Journal of Hematology (2015) Vol. 91, Iss. 1, pp. 151-165
Open Access | Times Cited: 139
Malignant inflammation in cutaneous T‐cell lymphoma—a hostile takeover
Thorbjørn Krejsgaard, Lise M. Lindahl, Nigel P. Mongan, et al.
Seminars in Immunopathology (2016) Vol. 39, Iss. 3, pp. 269-282
Open Access | Times Cited: 129
Page 1 - Next Page

Scroll to top